carbapenems

carbapenems
Name	Carbapenems
Tradename	Imipenem, Meropenem, Ertapenem, Doripenem
Routes of administration	Intravenous, Intramuscular
Legal status	Prescription-only medicine

carbapenems Carbapenems are a class of broad-spectrum beta-lactam antibiotics used to treat severe bacterial infections. They are typically reserved for serious or multidrug-resistant infections and are important in hospital formularies and infectious disease practice. Carbapenems occupy a critical role in clinical guidelines and antimicrobial stewardship programs.

Overview

Carbapenems were developed during the 1970s and 1980s and include agents such as imipenem, meropenem, ertapenem, and doripenem. These agents are beta-lactams structurally related to penicillins and cephalosporins and are integrated into treatment pathways in acute care settings such as intensive care units and surgical wards. Carbapenems appear on lists and formularies maintained by institutions like the World Health Organization, the Centers for Disease Control and Prevention, and national health services in countries including United States, United Kingdom, and Japan. Major pharmaceutical companies and research centers, for example Merck & Co., Sumitomo Pharma, and Eli Lilly and Company, contributed to their development and commercialization.

Medical Uses

Carbapenems are indicated for severe infections caused by susceptible organisms, including complicated intra-abdominal infections, complicated urinary tract infections, nosocomial pneumonia, and febrile neutropenia. Clinical practice guidelines from organizations such as the Infectious Diseases Society of America, the European Centre for Disease Prevention and Control, and country-level bodies like National Institute for Health and Care Excellence inform use in conditions like ventilator-associated pneumonia and complicated skin and soft tissue infections. They are often employed when pathogens show resistance to third-generation cephalosporins or fluoroquinolones produced by pathogens monitored by surveillance networks such as CDC Emerging Infections Program and European Antimicrobial Resistance Surveillance Network.

Mechanism of Action

Carbapenems exert bactericidal activity by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs) involved in peptidoglycan cross-linking. Their beta-lactam ring and carbapenem core confer high affinity for multiple PBPs in Gram-negative and Gram-positive bacteria, a feature examined in structural biology studies at institutions like National Institutes of Health and research published by teams affiliated with Harvard University and Stanford University. Enzymology research groups at universities such as University of Oxford and Massachusetts Institute of Technology have characterized interactions with PBPs and hydrolysis by beta-lactamases, including carbapenem-hydrolyzing class D and class B metallo-beta-lactamases described in reports by World Health Organization experts.

Resistance and Epidemiology

Carbapenem resistance has emerged globally, driven by carbapenemase enzymes (e.g., KPC, NDM, OXA-type) and by porin mutations and efflux mechanisms described in surveillance reports by Centers for Disease Control and Prevention, World Health Organization, and European Centre for Disease Prevention and Control. Notable outbreaks and dissemination have involved pathogens such as carbapenem-resistant Enterobacterales and carbapenem-resistant Acinetobacter baumannii tracked in investigations by public health agencies like Public Health England and research centers including Johns Hopkins University School of Medicine. High-profile cases and studies from regions such as South Asia, Europe, United States, and Brazil illustrate clonal expansion, plasmid-mediated transfer, and international spread facilitated by travel and healthcare networks analyzed by groups at Imperial College London and University of Toronto.

Pharmacokinetics and Metabolism

Pharmacokinetic profiles differ among agents: imipenem is co-administered with cilastatin to inhibit renal dehydropeptidase I and reduce renal metabolism, while meropenem, ertapenem, and doripenem have distinct plasma protein binding and half-lives influencing dosing regimens. Dosing adjustments for renal impairment follow guidance from regulatory agencies such as the Food and Drug Administration and the European Medicines Agency, and pharmacology texts from institutions like University of California, San Francisco and Mayo Clinic summarize elimination pathways, volume of distribution, and cerebrospinal fluid penetration relevant to treating meningitis and intra-abdominal infections.

Adverse Effects and Safety

Common adverse effects include gastrointestinal symptoms, hypersensitivity reactions in individuals with beta-lactam allergy histories, and central nervous system effects such as seizures reported with high-dose imipenem especially in patients with renal dysfunction. Safety profiles are documented in product labeling and post-marketing surveillance managed by regulators like the Food and Drug Administration and pharmacovigilance centers at organizations such as World Health Organization Uppsala Monitoring Centre. Stewardship initiatives at hospitals and academic centers including Cleveland Clinic and Massachusetts General Hospital emphasize risk–benefit assessment and monitoring.

Development and Clinical History

The discovery and clinical introduction of carbapenems involved academic–industry collaborations, patent filings, and clinical trials conducted in the late 20th century. Early development work at companies such as Merck & Co. and licensing arrangements with firms like Daiichi Sankyo led to market approvals by regulators including the Food and Drug Administration and subsequent inclusion in treatment guidelines produced by bodies like the Infectious Diseases Society of America. Ongoing research at universities such as University of Cambridge and pharmaceutical research divisions at Pfizer explores next-generation beta-lactamase inhibitors and combination therapies to restore activity against carbapenem-resistant organisms.

Category:Antibiotics